Takeda Class 1 new drug "Measatan Potassium Tablets" is about to be approved for sale

Recently, Takeda Pharmaceuticals according to the category 5.1 declaration of the United States Asatan potassium tablets listing application (acceptance number: JXHS1800028) is in the "in the approval" stage, is expected to be approved for listing by NMPA in the near future.
used to treat primary hypertension.
angiosin II is converted by angiosin I under the catalytic action of angiosinase.
angiosin II is the main booster of the nephrine-angiostrain system, which has a variety of physiological effects such as promoting vascular contraction, stimulating the synthesis and release of aldosterone, stimulating the heart and promoting renal re-absorption of sodium.
methadan potassium is an angiotensin II blocker developed by Takeda, an oral pre-drug that can be rapidly metabolized by esterase in the body as an active ingredient.
the latter can selectively block angiosculose II by binding to many tissues such as angiosmosis muscles and AT1 receptors in the adrenal glands to block angioconstrication and aldosterone secretion.
, its effect is not related to angiosin II synthesis pathway.
Azishatan's affinity for AT1 receptors is more than 10,000 times that of AT2 receptors.
at the 13th Oriental Cardiology Conference 2019, Takeda presented the results of the Phase III Clinical Study of Meatan Potassium on People with Hypertension in China (NCT02480764).
the study recruited 612 patients with primary hypertension who were randomly treated with 80 mg of measatan potassium (n=209), 40 mg (n=199) or 160 mg (n=204) of mesatan for 8 weeks of double-blind treatment.
study endpoints included changes in the baseline of systolic systolic blood pressure (scSBP) in the 8th week of the clinic (22-24 hours after the last drug was given), and scDBP in the sitting diastolic pressure (scDBP).
results showed that the decline in the scSBP valley value in the 8th week was significantly higher than that in the scSBP group (-24.2 vs -20.6 mm Hg; P-0.01) and the decline in the ScSBP valley value in the Measatan potassium 40 mg group was not inferior to that in the scSBP group (-22.5 vs. vs. -20.6 mmHg, p-0.18).
257 eligible subjects were included in abPM (24-hour dynamic blood pressure monitoring) subgroup analysis.
analysis showed that in week 8, the average of SBP and DBP in the 40mg and 80mg groups of 0 to 24 hours of dynamic blood pressure monitoring (8am to 7am) was lower than that of the 160mg group.
safety, the rates of treatment-related adverse events (TEAEs) were similar (52.8% to 56.5%) in each treatment group, and TEAEs were generally mild or moderate.
most common treatment-related TEAE was dizziness (1.9% in the 80mg group of measatan potassium; 1.5% in the 40mg group of methatan potassium; and 1.0% in the python group).
based on the above findings, Takeda submitted an application to NMPA for the listing of Measatan Potassium in July 2018.
first approved by the FDA for listing in 2011.
is currently listed in the United States, Canada, France, the United Kingdom and other countries around the world.
2019, Potassium Ashatan generated 76.7 billion yen in revenue for Takeda, or about 4.8 billion yuan, according to the New Pharma database of the Chinese Medicine Cube.